Taiho Pharmaceutical and Cullinan Oncology Establish Collaboration to Develop TAS6417, a Novel EGFR Tyrosine Kinase Inhibitor Taiho Pharmaceutical and Cullinan Oncology Establish Collaboration to Develop TAS6417, a Novel EGFR Tyrosine Kinase Inhibitor root2019-02-05T18:07:22+00:00February 5, 2019| Read More
Ex-Intarcia dealmaker lands $150M for new cancer drug startup Cullinan root2017-11-03T13:05:34+00:00October 3, 2017| Read More
Cullinan Oncology Secures $150 Million Series A Financing To Build Innovative Development Company Cullinan Oncology Secures $150 Million Series A Financing To Build Innovative Development Company root2017-11-08T10:54:46+00:00October 3, 2017| Read More
